Loading clinical trials...
Loading clinical trials...
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
TG Therapeutics, Inc.
NCT04047628 · Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, and more
NCT06663111 · Relapsing Remitting Multiple Sclerosis
NCT04602390 · Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
NCT06949956 · Relapsing Remitting Multiple Sclerosis
NCT05978531 · Relapsing Remitting Multiple Sclerosis
TG Therapeutics Investigational Trial Site
Pasadena, California
TG Therapeutics Investigational Trial Site
Aurora, Colorado
TG Therapeutics Investigational Trial Site
Lexington, Kentucky
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions